Termination of Three Declarations Authorizing Emergency Use of Medical Devices During the COVID-19 Pandemic
HHS terminates three emergency use declarations for medical devices related to COVID-19. This does not directly affect cosmetics or MoCRA compliance, but may impact businesses that also manufacture or distribute medical devices.
Aforeworn detected this change in the Cosmetics & Personal-Care (MoCRA) space on July 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Cosmetics businesses that also manufacture or distribute medical devices under EUAs should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately upon publication (July 2, 2026). Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Cosmetics & Personal-Care (MoCRA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Three EUA declarations for medical devices are terminated, ending emergency use authorizations
Who it affects
Cosmetics businesses that also manufacture or distribute medical devices under EUAs
What you must do
No action required for pure cosmetics businesses; those with medical device EUAs must transition to standard marketing pathways
Deadline
Immediately upon publication (July 2, 2026)
Never miss a change like this again
Aforeworn watches Cosmetics & Personal-Care (MoCRA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Cosmetics & Personal-Care (MoCRA)
- FDA Launches One-Day Inspectional Assessments to Strengthen and Expand Oversight
- FDA Grants Seventh Approval under the National Priority Voucher Pilot Program
- FDA Issues Guidance to Improve Collection of Pregnancy Safety Data for Drugs and Biologics
- FDA Expands AI Capabilities and Completes Data Platform Consolidation
- FDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV) Infection